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Objective To identify uses of WHO Model list of essential medicines (EM) and summarize studies 
examining essential medicines (EM) and national EM lists (NEMLs). 
Study design and setting In this scoping review, we searched PubMed, Scopus, WHO website and WHO 
Regional Databases for studies on NEMLs, reimbursement medicines lists, and WHO EML, with no date 
or language restrictions. 
Results 3,144 retrieved documents were independently screened by two reviewers; 100 full-text 
documents were analyzed; 37 contained data suitable for quantitative and qualitative analysis on EMs 
availability (11 documents), medicines for specific diseases (13 documents), and comparison of WHO 
EML and NEMLs (13 documents). From the latter, 2 documents analyzed the relevance of evidence from 
Cochrane systematic reviews for medicines that were on NEMLs but not on the WHO EML. EMs 
availability is still suboptimal in low-income countries. Availability of children formulations and EMs for 
specific diseases such as chronic, cancer, pain and reproductive health is suboptimal even in middle-
income countries. 
Conclusion WHO EML can be used as a basic set of medicines for different settings. More evidence is 
needed into how NEMLs can contribute to better availability of children formulations, pain and cancer 
medicines in developing countries. 
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What is new 
This is the first scoping review on the use of essential medicines concept. Two bibliographical databases 
and WHO regional databases were searched to find all relevant studies on the implementation of 
essential medicines concept. 
Key findings 
Countries varied greatly in the alignment of national essential medicines lists to the WHO essential 
medicines list and availability of essential medicines. Essential medicines availability is still suboptimal in 
low-income countries.  
What this adds to what is known 
Availability of essential medicines for specific diseases such as chronic, cancer, pain (suboptimal use of 
opioid medicines), reproductive health, pregnancy and children care and orphan diseases is suboptimal 
even in middle income countries, and medicines for hepatitis C are insufficiently available around the 
globe. 
What is the implication, what should change now 
More evidence is needed into how NEMLs can contribute to better availability of children formulations, 


















Medicines are the second most important component of healthcare budgets, second only to 
salaries [1]. The World Health Organization (WHO) considers relevant choices of medicines as the most 
cost-effective health intervention after childhood immunization [2]. The concept that some medicines 
are more “essential” than others is as relevant to the world nowadays as it was in 1975 when it was 
developed [3]. Currently, 146 countries have accepted the Essential Medicines concept, which guides 
reimbursement of medicines on the basis of public health importance, efficacy, safety and cost [4]. In 
brief, the idea is that medicines of the highest public health relevance should be made available on 
equal basis to all members of a population for free or at an affordable price [3]. Since 1977, WHO has 
been updating its EML every two years, with the latest 20th version for adults and the 6th version for 
children updated in 2017 [5]. The WHO EML can serve as a model list for country specific national 
essential medicines lists. 
National essential medicines lists (NEMLs) or reimbursed medicines lists are a key component of 
well-functioning health-care system [1]. NEMLs are the cornerstone of the national medicines policy; 
they should affect the pharmaceutical system at all levels: manufacturing, supply, prescribing and even 
donations, in order to guarantee individuals and populations all the medicines they really need [6,7]. 
NEMLs are developed and approved by the government of a country, and the most cost-effective 
medicines for infective and non-infective diseases should be included. Some countries have a unique 
NEML that is valid for the whole territory of the country, and other countries, especially those 
territorially diverse such as China [8], develop subnational/province/cantonal-level EMLs, based on 
regional needs and priority health-conditions to be treated. In smaller countries, such an approach could 















The selection of NEML remains a country’s responsibility, since the very concept is supposed to 
be flexible and adaptable to local circumstances [10]. 
Objective 
We performed to a scoping review of the peer-reviewed and grey literature that aimed to 
reporting empirical data concerning EMLs in order to synthesizes the knowledge on practical use of 
EMLs and provide a baseline to influence further research on the topic at a global scale. Specifically, we 
aimed to identify uses of WHO Model list of essential medicines (EM) and summarize studies examining 
essential medicines (EM) and national EM lists (NEMLs). The scoping review methodology [11,12] was 
used because the topic of EMs is complex and heterogeneous in nature and not amenable to a focused 
systematic review. We followed the methodology and guidance for the conduct of scoping reviews 
developed by members of the Joanna Briggs Institute and members of five Joanna Briggs Collaborating 
Centres [11]. We wrote a brief protocol for the scoping review (Supplementary document 1) but we did 
not register it.  
Methods 
Search strategy 
The search focuses on the following concepts: 1) Selection process, priority setting, 
methodology, expansion of the Ms list, policy; 2) Use, implementation, prescribing patterns; 3) 
Economic evaluation; 4) Impact, patient outcomes; 5) Pros and cons, attitude and opinion towards EMs 
formulary; 6) Specific diseases or group of diseases; 7) Alignment, rational use, prescribing practices, 
prescribing patterns; 8) EMs in the developing countries (middle and low income); 9) Availability, 
accessibility, supply of EMs (procurement) and 10) Critical comparison WHO EML – NML. Retrieved 
documents were coded in one or multiple categories by two evaluators (MMK, AJK). Topics excluded 















Modelling studies; 4) Technical report series (TRS; interventions in WHO EML); 5) Patents; 6) 
Bioequivalence studies and 7) EMs in emergency situations 8) lower than national level. In cases of 
disagreement, the third researcher was consulted (AM) and the differences were resolved by consensus. 
After defining concepts to be addressed in the scoping review, the primary search strategy was 
developed (AM) in consultation with an experienced librarian (AU), and conducted without time or 
language restrictions. We searched PubMed and SCOPUS on 25 November 2015. The PubMed search 
strategy was: "world health organization"[All Fields] AND ((essential medicine[All Fields] OR essential 
medicines[All Fields]) OR (national list[All Fields] OR national listing[All Fields] OR national lists[All 
Fields]) OR (reimbursement[All Fields] OR reimbursement'[All Fields] OR reimbursement's[All Fields] OR 
reimbursement features[All Fields] OR reimbursement for[All Fields] OR reimbursement intelligence[All 
Fields] OR reimbursementn2qod[All Fields] OR reimbursements[All Fields] OR reimbursements'[All 
Fields] OR reimbursement specialist[All Fields])), and was adapted for SCOPUS. The search was repeated 
on 4 December 2017, using the same search strategy. The search output was transferred to Endnote X5 
for Windows (Thomson Reuters, 2011), and de-duplicated. Two reviewers (MMK, AJK) checked the titles 
(and abstracts if available) for inclusion criteria. Further exclusions were performed after reading the full 
text of the documents. 
We also searched the grey literature, including the World Health Organization [13] website, as 
WHO provides leadership in global matters concerning global health, especially medicines, and 
articulates evidence-based policy options [14]. We searched WHO Essential medicines and health 
products information portal („Essential Medicines and Health Products Information Portal Medicine 
access>Rational Use“), as well as WHO Regional Databases: African Index Medicus – AIM, Index Medicus 
for the Eastern Mediterranean Region – IMEMR, Index Medicus for the South-East Asian Region – 
IMSEAR, Latin American and Caribbean Health Sciences Literature – LILACS, Western Pacific Region 















“essential”, “medicine(s)”, “drug(s)”, “WHO”. The same exclusion criteria were used as in the database 
search, and reports, resolutions and technical discussions were excluded. A liberal accelerated model 
[15] was used to search the gray literature, in which one reviewer (MMK) selected potentially inclusive 
titles, and the other (AJK) checked rejected titles for potential inclusion. Disputes were solved by 
agreement and consultation with the third researcher (AM). 
Analysis 
After finding the most frequent concepts, these were further refined, and investigated: 
availability of EMs in general, availability of EMs for specific diseases, and critical comparisons of WHO 
EML and NEMLs. For documents that reported on the content of EMLs, we analyzed the number of 
medicines that appeared only on the WHO Model list of essential medicines (EML), medicines that only 
appeared on NEMLs, medicines presented on both the WHO EML and NEMLs. We also reported the 
alignment (adherence) index or calculated it in cases where it was not reported but the document 
contained the data to allow the calculation. The alignment index was defined as number of medicines 
present both on WHO EML and NEML compared to number of medicines present only on an NEML [16] 
accompanied with the interquartile range (IQR) of the alignment index. All documents that contained 
data comparing the WHO EML and NEMLs, whether primary or secondary research studies, were used 
for data extraction. The data extraction for critical comparison of the WHO EML and NEMLs was done 
for the latest version of NEML available. If a country’s NEML was analyzed in several documents, the 
most recent document was included. Data extraction for included studies where some of the authors 
were involved was performed by non-involved authors. 
Since Preferred Reporting Items for Systematic Reviews and Meta-Analysis: extension for 
Scoping Reviews (PRISMA-ScR) are still being defined [17], we used the applicable items from the 
















In total, 3,144 documents were screened and 100 full text documents were analyzed by three 
reviewers (MMK, AM, KC) after deduplication (Figure 1). The most frequent concepts that emerged in 
these documents were: availability/accessibility of EMs (68 documents), EMs in low- and middle-income 
countries (65 documents) and EMs for specific diseases (49 documents). 15 documents (published from 
2006 to 2017) compared WHO and national EM lists (NEMLs). We excluded 63 documents which were 
out of the scope of the review (Supplementary Table 1). 
We analyzed 37 full documents that contained data suitable for quantitative or qualitative 
analysis: 11 documents on the general availability of EMs, 13 documents on availability of EMs for 
specific diseases, and 13 documents on head-to-head critical comparisons of WHO EML and NEMLs (See 
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Figure 1. Flow chart of the scoping review. Reasons for exclusion of 63 articles are presented in 


















In total, 11 documents reported on EM availability [19-29]. EMs availability (Table 1) remains 
suboptimal in low-income countries, while the situation is better in middle income countries, especially 
concerning generic EMs. Provision and availability of EMs (measured using WHO/Health Action 
International (HAI) methodology and WHO operational package for monitoring and assessing country 
pharmaceutical situations) [30,31] has improved (over 2003-2011 time period) compared to non-EMs in 
low- and lower middle-income countries, especially in the public sector, although availability still has not 
ensured equitable access [19]. In Sub-Saharan Africa, EMs contributed to the reduction of morbidity and 
mortality for the past 30 years, measured by infant mortality (which significantly dropped with the 
increase of measles and DTP immunization coverage) but EMs availability in public facilities remains 
alarmingly low [16]. 
Availability of EMs for specific diseases 
13 documents reported on availability of EM for specific diseases or populations. Availability of 
inhaled corticosteroids, pain medicines (especially opioid), cancer medicines, hepatitis C medicines, 
medicines for reproductive health and children formulations was found to be suboptimal 
(Supplementary Table 3) [32-44]. 
Alignment of NEMLs to the WHO EML 
NEML’s alignment with the WHO EML was reported in 13 documents (summarized in Table 2) 
[2,6,8,9,16,45-52]. The median number of medicines on NEMLs was 339, and ranged from 218 in 
Djibouti to 627 in the Philippines. The dates of the NEMLs ranged from 2006 to 2013. The average 
number of medicines that were at the same time on the latest NEML and the closest version of the WHO 
EML was 194, and ranged from 124 in Bosnia and Herzegovina to 283 in the Philippines. The number of 
medicines which were only on the NEML varied from 164 (Bosnia and Herzegovina) to 495 (Mexico), 















Herzegovina to 301 in Malawi (median 223). The median alignment index was 0.46 (interquartile range 
0.41 to 0.57). The lowest indices of alignment were reported in Brazil and Mexico (0.31), and the highest 
in Indonesia (0.79). 
Although Brazil had a special EML for children, there was a lack of special formulations of EMs 
even for indispensable therapeutic medicines for severe clinical conditions [45]. The number of special 
formulations for children was also reported less than needed for the burden of disease in China [53, 54] 
and South Africa [52]. 
We found two documents in which the use of Cochrane systematic reviews was analyzed to 
evaluate the evidence base for the medicines on the NEML in two countries [9, 47]. In these documents, 
the use of the Cochrane Database of systematic reviews was tested in addition to the WHO EML in 
revising NEMLs: one in a high income non-OECD country (Croatia) and the other in an upper middle-
income country (Bosnia and Herzegovina). The Cochrane Database of systematic reviews provided high 
quality evidence for 42 (8.3%) and 38 (11.4%) medicines (same or more benefits, including ones with 
serious side effects) justifying their inclusion on the NEML in these two countries, respectively. The 
Cochrane Database of systematic reviews provided evidence for exclusion from the NEML for 14 (2.8%) 
and 16 (4.8%) medicines in the two countries, respectively. 
Discussion 
EMs availability is still suboptimal in low- and middle-income countries, especially for specific 
diseases and populations including chronic diseases, reproductive health, pregnancy care, child health, 
cancer, and pain (low availability of opioid medicines and excessive NSAIDs availability). Hepatitis C 
medicines are not sufficiently available even in high-income countries. 
NEMLs differed greatly from the WHO EML. One reason is that a small number of developed 















medicines policies [6]. Furthermore, country standard treatment guidelines also do not align with the 
WHO EML [6].  
Other possible reasons could include different epidemiological circumstances worldwide 
concerning both communicable and non-communicable diseases, and some differences are expected 
and justifiable [8, 10]. Not all medicines are licensed in all countries due to different national medicines’ 
policies [9] and different strategic and marketing policies of medicines manufacturers. That is why the 
WHO EML was not intended to be reproduced on every NEML, but rather to serve as a guide to save 
costs and increase rational medicines availability and prescribing.  
The implementation of the concept of EMs has significantly reduced morbidity and mortality in 
many countries of the world in the past 30 years, particularly in developing countries [16], but still one 
third of the world population lacks reliable access to EMs [30]. Many EMs are available globally [55], 
partly due to the significant increase of the use of generic medicines, which has increased the availability 
of EMs. The concept of NEMLs is best developed in Africa and Southeast Asia, where almost all countries 
have adopted an NEML [8]. Nevertheless, according to the WHO, around 10 million lives could be saved 
annually by improving access to EMs, nearly half of those in Africa and South-East Asia [56]. Although 
the concept of EMs is widely accepted, and the need for periodic update is an important part of this 
concept, more than a third (36.8%) of low and middle-income countries assessed in 2014 have not 
updated EML between 2000 and 2012 [57]. 
Cochrane is an NGO in official relations with WHO [58] and has been striving to increase the use 
of Cochrane reviews to support decisions about additions or deletions of medicines to the WHO EML. In 
total, 177 reviews from 40 Cochrane Review Groups (range 1 to 19 reviews) have been used to inform all 
nine Reports of the WHO Expert Committee on the Selection and Use of Essential Medicines (including 















(range 2 to 41 reviews per report), published between 2000 and 2015 [59]. However, the WHO EML 
considers not only evidence of efficacy and harm, but also cost and regulatory status of medicines. Since 
the financial power of countries’ health-care systems varies worldwide, it is useful to consult the 
Cochrane Database of systematic reviews when making decisions on an NEML if financial resources and 
appropriate expertise are available [9,47]. 
The risk of bias/critical appraisal is not recommended for scoping reviews [11], so we did not 
formally evaluate the risk of bias.  One of the included studies was a review without a defined 
systematic search strategy and with a high risk of bias due to the commercial nature of the company 
publishing the document [6]. It had undefined financial support for conducting the review and 
undisclosed other conflicts of interest. 
The findings of this review should be interpreted with respect to several limitations. As we did 
not impose time limits to the search, some of the time-dependent variables and data are outdated. 
Although formal quality assessment could not be done for these studies, their quality could be 
considered low according to their weak designs (observational, cross sectional). Some studies on the 
availability or affordability of EMs used the standardized WHO research methodology [30,31]; other 
studies used very heterogeneous research methodologies, which made the analysis difficult. EM 
concepts keep evolving and the situation changes over time as medical policies change globally and 
locally. Furthermore, only two bibliographical databases were searched in this study, leaving the 
possibility that we might have omitted peer-reviewed studies on this topic that were not indexed on 
these databases. It was also impossible to cover all grey sources of data, so some of the evidence may 
still be missing, even in high-income countries, which had the highest transparency of the selection 















using PRESS [60], which is a possible limitation. We wrote the protocol for the scoping review, but did 
not formally register it, which may present a limitation. 
In conclusion, the WHO EML has helped the development of the EM concept worldwide, but 
more evidence is needed regarding how NEMLs can contribute to improving the availability of age-
appropriate formulations for children, as well as pain and cancer EMs, especially in developing 
countries. 
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Table 1. Availability of essential medicines (n = 11 articles) 
Author 
Year 





Essential medicines are 
more available than 
other medicines around 
the globe 
Bolivia, Brazil, Cameroon, 
Chad, China, Congo, Ethiopia, 
Ghana, Indonesia, Kenya, 
Malaysia, Mali, Mexico, 
Nicaragua, Nigeria, Pakistan, 
South Africa, Tajikistan, 
Tanzania, Thailand, Uganda, 
Yemen, India 
L, M In all sectors of the mean availability of medicines was found 
suboptimal 61.5% (IQR 20.6% -86.7%) but significantly higher for non-
essential medicines, 27.3% (IQR 3.6% -70.0%). Mean availability of 
essential medicines was 40.0% in the public sector and 78.1% in the 
private sector; compared to 6.6% and 57.1% for non-essential 
medicines respectively. The availability of medicines in the public sector 
was lower in countries with lower revenue. 






Availability, prices and 
affordability of essential 
medicines in Haiti 
Haiti L The availability of EMs was low, and the prices are very varied across 
sectors. More than 75% of Haitians live on less than 2 US $ / day; and 
most of the medicines were unavailable. The inclusion of medicines on 
the NEML and cooperation with the organizations responsible for the 
importation of medicines in Haiti, in particular the humanitarian 
organizations are the most important steps in ensuring access to 
medicines. 






Evaluation of availability, 
accessibility and 
prescribing pattern of 
medicines in the Islamic 
Republic of Iran 
Iran UM Good availability of medicines in pharmacies in the public sector. 
Management of medicines is good, the quality of storage meets the 
standards, limits the duration acceptable, and the quantity of drugs 
with expired expiration dates small. Centralized procurement and 
distribution of medicines contribute to it. An information service of the 
Ministry of Health actively provides information about the safe and 
rational use of medicines and health care professionals to the public. 
The availability of medicines is very good, very low cost of medicines is 
the result of state support to the national pharmaceutical industry, 
which is heavily subsidized. Approximately 85% of the population is 
covered by some form of health insurance, which subsidizes 70% of the 
price of the drug. Generic prescribing is essential and generic 











and prescribing pattern 
of medicines in Sudan 
Sudan LM The total availability of EMs in public and in private pharmacies in 
Sudan is satisfactory. The availability of medicines to treat some 
common diseases such as malaria and pneumonia in children may be 
considered satisfactory, but the availability of medicines for the 
treatment of other diseases, such as pneumonia in adults, could be 
improved. The rate of prescribing antibiotics is high and alignment to 
standard treatment guidelines of common diseases such as malaria and 























A national survey on 
availability, price and 
affordability of selected 
essential medicines for 
non-communicable 
diseases in Sri Lanka 
Sri Lanka LM Availability of selected EMs is high in the public and private sector. 
Most of the medicines are available to individuals with the lowest 
income. A wide variety of generic medicines is available in the private 
and public pharmacies, which increases the availability of medicines. 




Ewen 2017 Baseline assessment of 
WHO's target for both 
availability and 
affordability of essential 
medicines to treat non-
communicable 
diseases 
Afganistan, Bolivia, Burkina 
Faso, Burundi, Brazil, China, 
Colombia, Equador, Ethiopia, 
Haiti, India, Indonesia, Iran, 
Kyrgyzstan, Lao, Lebanon, 
Mauritius, Mexico, Moldova, 
Mongolia, Nicaragua, Sao 
Tome et Principe, Sudan, 
Tanzania, Tajikistan, Uganda, 
Ukraine 
 In low-income countries, 15.2% and 18.9% of lowest-priced generics 
met WHO's target in the public and private sectors, respectively, and 
2.6% and 5.2% of originator brands. In lower-middle income countries, 
23.8% and 23.2% of lowest priced generics, and 0.8% and 
1.4% of originator brands, met the target in the public and private 
sectors, respectively. In upper-middle income countries, the situation 
was better for generics but still suboptimal as 36.0% and 39.4% met 
the target in public and private sectors, respectively. For originator 
brands in upper-middle income countries, none reached the target in 
the public sector and 13.7% in the private sector. Across the 
therapeutic groups for lowest priced generics, CVD medicines in low-
income countries (11.9%), and CNS medicines in lower-middle (10.2%) 
and upper-middle income countries (33.3%), were least available and 
affordable in the public sector. In the private sector for lowest priced 
generics, CNS medicines were least available and affordable in all 
three country income groups (11.4%, 5.8% and 29.3% in low-, lower-
middle and upper-middle income countries respectively). 









antibiotic medicines in 
Malawi 
Malawi L Availability of the antimalarials was high in public and charity facilities 
(93% and 100%, respectively). However, availability of antibiotics was 
much lower (e.g. 40% availability of amoxicillin tablets/capsules in 
public health centres). Medicine prices were lower than reported from 
many other countries. 






The availability and 
affordability of selected 
essential medicines for 
chronic diseases in six 
low- and middle-income 
countries 
Bangladesh, Brazil, Malawi, 
Nepal, Pakistan and Sri Lanka 
LM, UM, 
L 
Availability of medicines for treatment of chronic diseases 
(hypertension, hyperlipidemia) was low. Availability of benzathine 
benzylpenicilline (treatment of rheumatic fever) was low in Bangladesh, 
Nepal and Sri Lanka. Streptokinase (a thrombolytic), which significantly 
reduces mortality in patients with myocardial infarction was not 
available in all countries. 




Saleh 2005 Are essential medicines 
in Malaysia accessible, 
affordable and available? 
Malaysia UM Most of the population of Malaysia has access to affordable EMs. If the 
medicines are procured by the private sector, availability is low. The 
average availability of EMs in Malaysia is very high (> 95.0%), in some 
areas of the region is lower e.g. Sabah, <80.0%. 








management of essential 
medicines in public 
Burkina Faso L Availability of hospital EMs originators in public hospitals (emergency 
EMs that do not exist in the form of generic) is low. The availability of 
generic medicines is better. The consequence is that some patients 
have to use the services of the private sector, where pay high prices for 


















hospitals of Burkina Faso listed medicines. Some essential hospital originator medicines are not 
available in the private sector (for example, a solution for injections of 
magnesium sulphate). 
- There is no local production of medicines. 
- Generic medicines are more available than originator in all areas 






affordability in Sri Lanka 
Sri Lanka LM Generic medicines have good prices and are available. Originator 
medicines are more expensive and less available. The differences in 
prices in the private and public pharmacies were not observed. High 
availability of generic medicines at all times ensure availability of 
medicines and equality for patients. Even six years after stopping prices 
monitoring, prices have not increased dramatically. 




L – low-income, M – middle-income, LM – lower middle-income, UM – upper middle-income, H – high-income country, EMs – essential 
medicines, IQR – interquartile range 
 












Total No of 
molecules on 
NEML 









Total No of 
medicines on 
NEML only* 
















Bangladesh LM 162.9 2.8 1982 - 160 160 160 - - 1.00 - - - 
Bosnia and 
Herzegovina 
UM 3.8 9.6 - 2013 334# 414 124 164 92 0.37 declarative no no 
Brazil UM 207.8 8.3 1964 2012 468 374 145 339 286 0.31 - passive yes 
Bhutan LM 0.7 3.6 - 2007 299 - - - - - - - - 
Cameroon LM 23.3 4.1 - - - - - - - 0.49 - - - 
Chad L 14.1 3.6 - - - - - - - 0.49 - - - 
China UM 1376.1 5.5 1982 2012 342 374 134 297 222 0.39 no passive - 
Congo L 4.6 4.3 - 2006 264 - - - - - - - - 
Croatia H non-OECD 4.2 7.8 - 2012 509‡ 359 188 321 42 0.37 declarative no no 
Djibouti LM 0.8 10.6 - 2007 218 - - - - - - - - 
Egypt LM 91.5 5.6 - 2006 385 - - - - - - - - 
Ethiopia L 102.4 4.9 1980 2010 - - - - - - - - - 















India LM 1311.1 4.7 1996 2011 352 374 156 275 227 0.44 yes passive - 
Indonesia LM 257.6 2.8 1978 2014 323 374 256 215 175 0.79 - - - 
Kenya LM 46.1 5.7 1981 2016 285 374 207 218 224 0.73 - - - 
Latvia H non-OECD 1.9 5.9 - 2007 313 - - - - - - - - 
Libya UM 6.3 5 - 2006 584 347 270 314 52 0.46 no - - 
Malawi L 17.2 11.4 1991 2009 318 374 130 216 301 0.41 - - - 
Malaysia UM 30.3 4.2 1995 2014 321         
Mali L 17.6 6.9 - - - - - - - 0.57 - - - 
Mexico UM 127.1 6.3 1984 2010 771 321 236 495 - 0.31 - - - 
Moldova LM 4.1 10.3 - 2006 447 - - - - - - - - 
Nepal L 28.9 5.8 1986 2011 321 - - - - - - - - 
Nigeria LM 182.2 3.7 1987 - - - - - - 0.61 - - - 
Papua New 
Guinea 
LM 7.6 4.3 - 2012 - - - - - - - - - 
Philippines LM 100.7 4.7 - 2008 627† 374 283 439 148 0.45 - yes - 
Senegal UM 15.1 4.7 - - - - - - - 0.43 - - - 
South Africa LM 54.5 8.8 1996 2012 339 374 201 416 230 0.59 - - yes 
Sri Lanka LM 20.7 3.5 - 2006 335 - - - - - - - - 
Tanzania L 53.5 5.6 1991 2013 440 374 186 427 245 0.42 - - - 
Uganda L 39.1 7.2 - - - - - - - 0.63 - - - 
Yemen LM 26.8 5.6 - 2007 309 - - - - - - - - 
L – low-income, UM – upper middle-income, LM – lower middle-income, H non-OECD – high, not members of Organisation for Economic Co-operation and 
Development, GDP – gross domestic product, EML – essential medicines list, WHO – World Health Organization, EMB – Evidence-based medicine. Alignment 
(adherence) index – proportion of medicines from the WHO Model List of Essential Medicines on each national EML to the total number of medicines on 
national EML. 
*Including duplicates for different indications. 
†Basic and supplementary list. 























83 full documents 
2 duplicates 
54 documents meeting 
exclusion criteria 
PubMed strategy 1 
(301 titles) 
PubMed strategy 2 
(497 titles) 







69 full documents 
Duplicates and excluded 
documents (2883 titles) 
2034 titles 922 titles 
13 full documents 
1 full document was not 
found 
